Discharge of Acute Coronary Syndrome Patients on Sub-Optimal Dual Anti-Platelet Therapy: A Single Center Experience.
Clopidogrel
Dual anti-platelet Therapy
Therapeutic Inertia
Ticagrelor
Journal
Cardiovascular drugs and therapy
ISSN: 1573-7241
Titre abrégé: Cardiovasc Drugs Ther
Pays: United States
ID NLM: 8712220
Informations de publication
Date de publication:
10 May 2024
10 May 2024
Historique:
accepted:
20
02
2024
medline:
10
5
2024
pubmed:
10
5
2024
entrez:
10
5
2024
Statut:
aheadofprint
Résumé
To identify and quantify the reasons why acute coronary syndrome (ACS) patients undergoing stenting at the University of New Mexico Hospital (UNMH) were prescribed sub-optimal dual antiplatelet therapy (DAPT) at discharge, and to identify practice patterns that could potentially lead to improved DAPT treatment for these patients. We reviewed electronic medical records and cardiac catheterization records of 326 patients who underwent percutaneous coronary intervention (PCI) at UNMH between January 1, 2021, and June 30, 2022 and identified 229 ACS patients who survived until discharge. Demographic and clinical characteristics relevant to P2Y The 229 ACS patients included 87 (38.0%) appropriately discharged on ticagrelor/prasugrel, 63 (27.5%) appropriately discharged on clopidogrel, 75 (32.8%) discharged on sub-optimal clopidogrel, and 4 (1.7%) not discharged on a P2Y At the University of New Mexico, a safety-net hospital, increasing financially restricted access to ticagrelor/prasugrel could help up to 24.5% of ACS patients reduce their risk of ischemic events. For patients admitted on clopidogrel DAPT, escalating to ticagrelor/prasugrel could reduce ischemic risk in 7.4%. Expanding and improving healthcare insurance coverage might reduce the frequency of discharge on sub-optimal P2Y
Identifiants
pubmed: 38727897
doi: 10.1007/s10557-024-07563-3
pii: 10.1007/s10557-024-07563-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001449
Pays : United States
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Harrington RA, Becker RC, Ezekowitz M et al. Antithrombotic therapy for coronary artery disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:513S-548S. https://doi.org/10.1378/chest.126.3_suppl.513S
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndrome. N Engl J Med. 2009;361:1045–57. https://doi.org/10.1056/NEJMoa0904327
doi: 10.1056/NEJMoa0904327
pubmed: 19717846
Chen HB, Zhang XL, Liang HB, Liu XW, Zhang XY, Huang BY, Xiu J. Meta-analysis of randomized controlled trials comparing risk of major adverse cardiac events and bleeding in patients with prasugrel versus clopidogrel. Am J Cardiol. 2015;116:384–92. https://doi.org/10.1016/j.amjcard.2015.04.054
doi: 10.1016/j.amjcard.2015.04.054
pubmed: 26051379
Chen W, Zhang C, Zhao J, et al. Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: a network meta-analysis. Clin Cardiol. 2021;44:488–94. https://doi.org/10.1002/clc.23536
doi: 10.1002/clc.23536
pubmed: 33704801
pmcid: 8027588
Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice guidelines. J Am Coll Cardiol. 2022;79:e21–129. https://doi.org/10.1016/j.jacc.2021.09.006
doi: 10.1016/j.jacc.2021.09.006
pubmed: 34895950
Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-thoracic surgery (EACTS). Eur Heart J. 2018;39:213–60. https://doi.org/10.1093/eurheartj/ehx419
doi: 10.1093/eurheartj/ehx419
pubmed: 28886622
Völz S, Petursson P, Odenstedt J, et al. Ticagrelor is not superior to clopidogrel in patients with acute coronary syndromes undergoing PCI: a report from Swedish coronary angiography and Angioplasty Registry. Journal of the American Heart Association. J Am Heart Assoc. 2020;9:e015990. https://doi.org/10.1161/JAHA.119.015990
doi: 10.1161/JAHA.119.015990
pubmed: 32662350
pmcid: 7660716
Yudi MB, Clark DJ, Farouque O, et al. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Intern Med J. 2016;46:559–65. https://doi.org/10.1111/imj.13041
doi: 10.1111/imj.13041
pubmed: 26909472
DiNicolantonio JJ, Serebruany VL. Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports. Ther Adv Cardiovasc Dis. 2013;7:5–9. https://doi.org/10.1177/1753944712468627
doi: 10.1177/1753944712468627
pubmed: 23393061
Gaubert M, Laine M, Richard T, et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. Int J Cardiol. 2014;173:120–1. https://doi.org/10.1016/j.ijcard.2014.02.028
doi: 10.1016/j.ijcard.2014.02.028
pubmed: 24612612
Peasah SK, Mager D, Munshi KD, Huang Y, Henderson R, Swart EC, Neilson L, Good CB. Real-world use and outcomes of oral antiplatelets among patients with acute coronary syndrome: a retrospective cohort study. Drugs-Real World Outcomes. 2022 Mar;1:1–7. https://doi.org/10.1007/s40801-021-00283-2
Ozaki AF, Jackevicius CA, Chong A, et al. Hospital-level variation in ticagrelor use in patients with acute coronary syndrome. J Am Heart Assoc. 2022;11:e024835. https://doi.org/10.1161/JAHA.121.024835
doi: 10.1161/JAHA.121.024835
pubmed: 35766263
pmcid: 9333376
Kumar A, Lutsey PL, St. Peter WL, et al. Prescription patterns of P2Y12 inhibitors following revascularization in the United States: 2013–2018. Clin Translation Sci. 2023;16:1886–97. https://doi.org/10.1111/cts.13596
doi: 10.1111/cts.13596
Wiens EJ, Leon SJ, Whitlock R, Tangri N, Shah AH. Ticagrelor as compared to clopidogrel following percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2023;198:26–32. https://doi.org/10.1016/j.amjcard.2023.03.012
doi: 10.1016/j.amjcard.2023.03.012
pubmed: 37196530
Wang Y, Cavallari LH, Brown JD, Thomas CD, Winterstein AG. Assessing the clinical treatment dynamics of antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention in the US. JAMA Netw Open. 2023;6:e238585. https://doi.org/10.1001/jamanetworkopen.2023.8585
doi: 10.1001/jamanetworkopen.2023.8585
pubmed: 37067798
pmcid: 10111179
Senguttuvan NB, Sankaran R, Rajeev Y, et al. Effect of discontinuation of ticagrelor and switching-over to other P2Y12 agents in patients with acute coronary syndrome: a single-center real-world experience from India. Egypt Heart J. 2021;73:1–8. https://doi.org/10.1186/s43044-020-00128-3
doi: 10.1186/s43044-020-00128-3
Walker AL, Sorensen T, Gabriel PP, et al. Ticagrelor use in acute myocardial infarction: balancing evidence-based medicine with affordability. J Am Coll Clin Pharm. 2018;1:58–61. https://doi.org/10.1002/jac5.1010
doi: 10.1002/jac5.1010
pubmed: 30637378
pmcid: 6326582
Rodwin BA, Lu D, Giaimo A, et al. Patient and hospital characteristics associated with ticagrelor uptake in acute MI: an analysis of the chest Pain–MI Registry. Internat J Card. 2020;304:14–20. https://doi.org/10.1016/j.ijcard.2020.01.029
doi: 10.1016/j.ijcard.2020.01.029
Faridi KF, Garratt KN, Kennedy KF et al. Physician and hospital utilization of P2Y12 inhibitors in ST-segment–elevation myocardial infarction in the United States: a study from the National Cardiovascular Data Registry’s Research to Practice Initiative. Circulation: Cardiovasc Qual Outcomes. 2020;13:e006275. https://doi.org/10.1161/CIRCOUTCOMES.119.006275
Hammer A, Krammel M, Aigner P, et al. The impact of preclinical high potent P2Y12 inhibitors on decision making at discharge and clinical outcomes in patients with acute coronary syndrome. J Clin Med. 2023;12:4094. https://doi.org/10.3390/jcm12124094
doi: 10.3390/jcm12124094
pubmed: 37373788
pmcid: 10299011
Aujoulat I, Jacquemin P, Rietzschel E et al. Factors associated with clinical inertia: an integrative review. Adv Med Ed Pract. 2014:141–7. https://doi.org/10.2147/AMEP.S59022
García-Macías JA, Palazon-Bru A, Carbonell-Torregrosa MÁ, Navarro-Juan M, Gil-Guillén VF. Therapeutic inertia in anti-platelet therapy in patients with a cardiovascular event attended in an emergency department. Curr Med Res Opin. 2019;35:455–9. https://doi.org/10.1080/03007995.2018.1469480
doi: 10.1080/03007995.2018.1469480
pubmed: 29690773
Biswas M, Kali MS, Biswas TK, Ibrahim B. Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. Platelets. 2021;32:591–600. https://doi.org/10.1080/09537104.2020.1792871
doi: 10.1080/09537104.2020.1792871
pubmed: 32664772
Galli M, Franchi F, Rollini F, et al. Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Rev Clin Pharmacol. 2021;14:963–78. https://doi.org/10.1080/17512433.2021.1927709
doi: 10.1080/17512433.2021.1927709
pubmed: 33993817
pmcid: 9008593
You SC, Rho Y, Bikdeli B, et al. Association of Ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA. 2020;324:1640–50. https://doi.org/10.1001/jama.2020.16167
doi: 10.1001/jama.2020.16167
pubmed: 33107944
pmcid: 7592033
Navarese EP, Khan SU, Kołodziejczak M, et al. Comparative efficacy and safety of oral P2Y12 inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation. 2020;142:150–60. https://doi.org/10.1161/CIRCULATIONAHA.120.046786
doi: 10.1161/CIRCULATIONAHA.120.046786
pubmed: 32468837
pmcid: 7489363
Parodi G, Storey RF. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Euro Heart J: Acute Cardiovasc Care. 2015;4:555–60. https://doi.org/10.1177/2048872614554108
doi: 10.1177/2048872614554108